Mergers & Acquisitions - Bristol-Myers Squibb, Mergers & Acquisitions

Filter

Popular Filters

Bristol-Myers enters option deal to acquire F-star Alpha and FS102

28-10-2014

US pharma major Bristol-Myers Squibb has entered into an agreement that provides it with the exclusive…

BiotechnologyBristol-Myers SquibbF-star AlphaFS102Mergers & AcquisitionsOncology

Bristol-Myers acquires iPierian for $175 million upfront, plus $550 possible milestones

Bristol-Myers acquires iPierian for $175 million upfront, plus $550 possible milestones

30-04-2014

US pharma major Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused…

BiotechnologyBristol-Myers SquibbiPierianIPN007Mergers & AcquisitionsNeurological

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

31-03-2014

Multinational drugmakers might be crying themselves hoarse that India does not protect innovation - that…

Asia-PacificBristol-Myers SquibbFinancialGlaxoSmithKlineIndiaMerck & CoMergers & AcquisitionsMylan LaboratoriesPatentsPharmaceuticalSanofi

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

17-03-2014

Shares of Five Prime Therapeutics leapt 15% to $21.48 in early trading, after the company said it has…

Bristol-Myers SquibbFive Prime TherapeuticsLicensingMergers & AcquisitionsOncologyPharmaceutical

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

19-12-2013

Confirming recent runors, Anglo-Swedish drug major AstraZeneca revealed this morning that it will acquire…

AstraZenecaBristol-Myers SquibbDiabetesExenatide InjectionMergers & AcquisitionsOnglyzaPharmaceutical

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Briefs: Elan/Royalty Pharma; Meda takeover statement; priority review for metreleptin; clinical hold on Pluristem trial

05-06-2013

Ireland-based Elan Corp (NYSE: ELN) has won an order from a US judge temporarily blocking Royalty Pharma…

AstraZenecaBristol-Myers SquibbElanLegalMedaMergers & AcquisitionsmetreleptinNorth AmericaPharmaceuticalPluristem TherapeuticsRegulationRoyalty Pharma

The Medicines Company in over $105 million deal with Bristol-Myers for Recothrom; buys Incline Thera

14-12-2012

Pharma major Bristol-Myers Squibb (NYSE: BMY) and fellow-USA-based The Medicines Company (Nasdaq: MDCO)…

Bristol-Myers SquibbIncline TherapeuticsIonsysLicensingMergers & AcquisitionsNeurologicalPharmaceuticalRecothromThe Medicines Company

Synergy Pharma gains rights to shingles drug from Bristol-Myers

28-08-2012

US biopharma firm Synergy Pharmaceuticals (Nasdaq: SGYP) has signed an asset purchase agreement with…

Anti-viralsBiotechnologyBristol-Myers SquibbFV-100Mergers & AcquisitionsSynergy Pharmaceuticals

Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action

02-07-2012

Having rejected a media reported $22 a share offer from the company earlier this year, US biotech firm…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbBydureonByettaDiabetesEli LillyMergers & AcquisitionsPharmaceutical

Amylin said to be attracting several Big Pharma suitors

16-05-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Investor Icahn slams Amylin for not revealing B-MS bid

05-04-2012

Billionaire US investor Carl Icahn has sent a blistering open letter to the board of US biotech company…

AmylinBiotechnologyBristol-Myers SquibbMergers & AcquisitionsPharmaceutical

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis

29-03-2012

There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Bristol-Myers to buy hep C drug developer for $2.5 billion

09-01-2012

Looking to bolster its drug pipeline in the face of US patent expiry of one of its best selling drugs,…

Anti-viralsBristol-Myers SquibbInhibitexMergers & AcquisitionsPharmaceutical

Back to top